What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report Amgen's unaudited financial results for the second quarter and first half of 2018 and to furnish the associated press release, which contains detailed financial information and the company's financial position as of June 30, 2018.

Why does Amgen present non-GAAP financial measures?

Amgen presents non-GAAP financial measures because they believe these measures provide useful supplementary information and facilitate additional analysis for investors. They are intended to enhance the understanding of the company's financial performance and future prospects by allowing for better comparisons of ongoing business operations across different periods, excluding certain items that may distort period-to-period comparability.

What types of expenses does Amgen exclude from its GAAP results to calculate non-GAAP measures?

Amgen typically excludes acquisition-related expenses (primarily amortization of purchased intangible assets), net charges related to restructuring initiatives, and certain expenses associated with judgments or settlements from legal proceedings. They believe these exclusions provide a more meaningful evaluation of current operating performance and facilitate comparisons to past performance.

What is Free Cash Flow (FCF) and why is it reported?

Free Cash Flow (FCF) is presented as an additional measure of Amgen's liquidity. It is calculated by subtracting capital expenditures from operating cash flow, both determined in accordance with GAAP. The company believes FCF provides a further measure of its ability to generate cash from its operations after accounting for necessary investments in its business.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on July 26, 2018, to report its unaudited financial results for the second quarter and first half of 2018. The filing primarily serves to furnish a press release detailing these results and the company's financial position as of June 30, 2018. Investors should note Amgen's use of non-GAAP financial measures, which they believe provide a more enhanced and comparable view of ongoing operational performance. The press release, which is incorporated by reference, outlines Amgen's specific adjustments made to GAAP figures to arrive at non-GAAP earnings per share, operating income, net income, and other metrics. Key exclusions from GAAP include acquisition-related expenses (primarily amortization of acquired intangible assets), net charges from restructuring initiatives, and certain legal settlement costs. The company also provides Free Cash Flow (FCF) as an additional liquidity measure. Investors are encouraged to review the detailed reconciliations provided in the press release to fully understand the differences between GAAP and non-GAAP reporting.

Key Highlights

1Amgen Inc. (AMGN) reported its unaudited financial results for the three and six months ended June 30, 2018, via an 8-K filing on July 26, 2018.
2The filing includes a press release (Exhibit 99.1) containing detailed financial performance and position information.
3Amgen utilizes non-GAAP financial measures, including non-GAAP EPS, operating income, and net income, to provide supplemental insights into operational performance.
4Key adjustments to GAAP figures for non-GAAP reporting include acquisition-related expenses (amortization of intangibles), restructuring charges, and certain legal settlements.
5The company also presents Free Cash Flow (FCF) as a measure of liquidity, calculated as operating cash flow minus capital expenditures.
6Reconciliations between GAAP and non-GAAP financial measures are provided within the press release for investor clarity.

AMGEN INC 8-K Report, Financial Results (Jul 26, 2018)

Summary

Key Highlights

Frequently Asked Questions